Refractory ascites-the contemporary view on pathogenesis and therapy.
Beata Kasztelan-SzczerbinskaHalina Cichoz-LachPublished in: PeerJ (2019)
Refractory ascites (RA) refers to ascites that cannot be mobilized or that has an early recurrence that cannot be prevented by medical therapy. Every year, 5-10% of patients with liver cirrhosis and with an accumulation of fluid in the peritoneal cavity develop RA while undergoing standard treatment (low sodium diet and diuretic dose up to 400 mg/day of spironolactone and 160 mg/day of furosemide). Liver cirrhosis accounts for marked alterations in the splanchnic and systemic hemodynamics, causing hypovolemia and arterial hypotension. The consequent activation of renin-angiotensin and sympathetic systems and increased renal sodium re-absorption occurs during the course of the disease. Cirrhotic patients with RA have poor prognoses and are at risk of developing serious complications. Different treatment options are available, but only liver transplantation may improve the survival of such patients.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- cell free
- newly diagnosed
- disease activity
- chronic kidney disease
- ejection fraction
- healthcare
- ankylosing spondylitis
- angiotensin converting enzyme
- physical activity
- angiotensin ii
- free survival
- prognostic factors
- peritoneal dialysis
- heart failure
- systemic lupus erythematosus
- peripheral blood
- stem cells
- weight loss
- interstitial lung disease
- risk factors
- bone marrow
- atrial fibrillation
- combination therapy
- systemic sclerosis